 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||||| bimatoprost ophthalmic (T4032) / Thea Laboratories
Trial completion: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan (clinicaltrials.gov) - Mar 21, 2024
P3, N=684, Completed, Sponsor: Laboratoires Thea
Active, not recruiting --> Completed
- ||||| bimatoprost ophthalmic (T4032) / Thea Laboratories
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan (clinicaltrials.gov) - Dec 1, 2023
P3, N=684, Active, not recruiting, Sponsor: Laboratoires Thea
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=500 --> 684 | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
- || bimatoprost ophthalmic (T4032) / Thea Laboratories
Trial completion: Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan (clinicaltrials.gov) - Nov 14, 2023
P1, N=40, Completed, Sponsor: Laboratoires Thea
Recruiting --> Active, not recruiting | N=500 --> 684 | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024 Not yet recruiting --> Completed
- || bimatoprost ophthalmic (T4032) / Thea Laboratories
New P1 trial: Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan (clinicaltrials.gov) - Feb 15, 2023
P1, N=40, Not yet recruiting, Sponsor: Laboratoires Thea
- |||||| bimatoprost ophthalmic (T4032) / Thea Laboratories
Enrollment open: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan (clinicaltrials.gov) - Jul 6, 2022
P3, N=500, Recruiting, Sponsor: Laboratoires Thea
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| bimatoprost ophthalmic (T4032) / Thea Laboratories
New P3 trial: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan (clinicaltrials.gov) - May 30, 2022
P3, N=500, Not yet recruiting, Sponsor: Laboratoires Thea
- ||||||| bimatoprost ophthalmic (T4032) / Thea Laboratories
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Efficacy and Safety Assessment of T4032 Versus Lumigan (clinicaltrials.gov) - Jul 28, 2021
P3, N=485, Completed, Sponsor: Laboratoires Thea
Not yet recruiting --> Recruiting Recruiting --> Completed | N=360 --> 485 | Trial completion date: May 2020 --> Feb 2021 | Trial primary completion date: Apr 2020 --> Feb 2021
- |||||||||| bimatoprost ophthalmic (T4032) / Thea Laboratories
New P3 trial: Efficacy and Safety Assessment of T4032 Versus Lumigan (clinicaltrials.gov) - Jan 31, 2019
P3, N=360, Recruiting, Sponsor: Laboratoires Thea